Co-Authors
This is a "connection" page, showing publications co-authored by Luke Moore and Michael Rayment.
Connection Strength
0.751
-
Real-world evaluation of COVID-19 lateral flow device (LFD) mass-testing in healthcare workers at a London hospital; a prospective cohort analysis. J Infect. 2021 10; 83(4):452-457.
Score: 0.240
-
Serological assays for delayed SARS-CoV-2 case identification - Author's reply. Lancet Respir Med. 2020 10; 8(10):e74.
Score: 0.226
-
Association between SARS-CoV-2 exposure and antibody status among healthcare workers in two London hospitals: a cross-sectional study. Infect Prev Pract. 2021 Sep; 3(3):100157.
Score: 0.060
-
SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (React 2): diagnostic accuracy study. BMJ. 2021 03 02; 372:n423.
Score: 0.058
-
Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence survey. Thorax. 2020 12; 75(12):1082-1088.
Score: 0.056
-
Point-of-care serological assays for delayed SARS-CoV-2 case identification among health-care workers in the UK: a prospective multicentre cohort study. Lancet Respir Med. 2020 09; 8(9):885-894.
Score: 0.056
-
Non-invasive saliva specimens for the diagnosis of COVID-19: caution in mild outpatient cohorts with low prevalence. Clin Microbiol Infect. 2020 Dec; 26(12):1711-1713.
Score: 0.056